Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (1)

Search Parameters:
Keywords = Flacourtiaceae

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
4 pages, 415 KiB  
Article
Isolation and Cytotoxic Investigation of Flacourtin from Oncoba spinosa
by Olaoye S. Balogun, Olukayode S. Ajayi and Olayinka S. Lawal
Medicines 2016, 3(4), 31; https://doi.org/10.3390/medicines3040031 - 6 Dec 2016
Cited by 3 | Viewed by 4115
Abstract
Background: Oncoba spinosa, an endangered medicinal plant whose secondary metabolites have not been extensively profiled, and which is hitherto yet to be examined for cytotoxicity, is being investigated in this study. Methods: Leaves of Oncoba spinosa (800 g) were extracted with 95% aqueous [...] Read more.
Background: Oncoba spinosa, an endangered medicinal plant whose secondary metabolites have not been extensively profiled, and which is hitherto yet to be examined for cytotoxicity, is being investigated in this study. Methods: Leaves of Oncoba spinosa (800 g) were extracted with 95% aqueous methanol. The crude extract was partitioned with n-hexane and the resultant defatted extract was extensively chromatographed on silica gel to yield compound 1 which was subjected to spectroscopic analysis. A brine shrimps lethality test was used to establish the cytotoxicity potentials of the isolated compound and the plant extracts. Results: Compound 1 was elucidated as flacourtin, 3-hydroxy-4-hydroxymethylphenyl-6-O-benzoyl-β-d-glucopyranoside. The LD50 values obtained were less than 1000 µg/mL for flacourtin and the plant extracts. Conclusion: Flacourtin is being reported for the first time in the O. spinosa. The preliminary toxicity assay indicated that flacourtin and the plant extracts were not cytotoxic; thus, the tradomedicinal uses of the plant may portend no danger. Full article
(This article belongs to the Special Issue Plant Medicines for Clinical Trial)
Show Figures

Figure 1

Back to TopTop